{"brief_title": "Consistency Lots Vaccine Study (V260-009)", "brief_summary": "This study was designed to evaluate consistency in the antibody response to three manufactured lots of an investigational Rotavirus Vaccine.", "condition": ["Rotavirus Infections"], "intervention_type": ["Biological", "Biological"], "intervention_name": ["rotavirus vaccine, live, oral, pentavalent", "Placebo"], "description": ["Three oral doses (~8.81 X 10^7 IU/Dose for Lot 1; ~8.01 X 10^7 IU/Dose for Lot 2; and ~6.91 X 10^7 IU/Dose for Lot 3) of RotaTeq\u2122 (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination", "Placebo-matching RotaTeq\u2122 administered at 3 separate visits scheduled 4 to 10\nweeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"], "arm_group_label": ["RotaTeq\u2122 Lot 1", "RotaTeq\u2122 Lot 2", "RotaTeq\u2122 Lot 3", "Placebo"], "other_name": ["V260", "RotaTeq\u2122"], "criteria": "Inclusion Criteria: - Healthy infants Exclusion Criteria: - History of abdominal disorders from a birth defect, intussusception, or abdominal surgery - Known or suspected problems with the immune system - Fever at time of immunization - Prior administration of a rotavirus vaccine - History of known prior rotavirus disease, chronic diarrhea, or failure to thrive.", "gender": "All", "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "healthy_volunteers": "Accepts Healthy Volunteers", "mesh_term": ["Rotavirus Infections", "Vaccines"], "id": "NCT00092456"}